Causal Linkage Between Angiotensin-converting Enzyme 2 and Risk of Lung Cancer: a Bidirectional Two-sample Mendelian Randomization Study

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Jul 23

PMID 39040892

Authors

Shubin Chen

Ruiling Ning

Wei Jiang

Shaozhang Zhou

Qitao Yu

Haijie Gan

Affiliations

Soon will be listed here.

Abstract

Background: Observational studies suggest a connection between ACE2 (angiotensin-converting enzyme 2) and lung cancer. However, it's not apparent if confounding variables are interfering with the link. Therefore, we aimed to define the relationships between ACE2 and the risk of lung cancer.

Methods: With the aim of developing genetic tools, we selected SNPs substantially associated with ACE2 using a statistically significant criterion. The relevant SNPs were then taken from the lung cancer GWAS dataset for additional research. After that, we used two-sample Mendelian randomization (MR) to ascertain if ACE2 is causally linked to the risk of developing lung cancer. To investigate the causal links' directions, we also performed a reverse MR analysis.

Results: According to our findings, there is strong evidence that ACE2 is linked to a decreased chance of developing lung cancer (odds ratio: 0.94; 95% confidence interval: 0.90-0.98; = 0.0016). The IVW method, the major MR analysis, was not impacted by heterogeneity in any of the analyses, according to Cochrane's Q test ( = 0.207). The MR-Egger intercept ( = 0.622) showed no indication of horizontal pleiotropy in any of the investigations. Outlier SNPs were not detected by the MR-PRESSO global test ( = 0.191). The leave-one-out analysis was performed, and the results showed a steady outcome. Nonsignificant causal estimates between lung cancer and ACE2 were produced by reverse MR analysis.

Conclusion: MR investigation revealed a significant causal link between ACE2 and the risk of getting lung cancer. These findings may have implications for public health measures aimed at reducing the incidence of lung cancer.

References

Burgess S, Butterworth A, Thompson S . Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013; 37(7):658-65. PMC: 4377079. DOI: 10.1002/gepi.21758. View

Zhong J, Ye J, Jin H, Yu X, Yu H, Zhu D . Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression. Regul Pept. 2010; 166(1-3):90-7. DOI: 10.1016/j.regpep.2010.09.005. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Skrivankova V, Richmond R, Woolf B, Yarmolinsky J, Davies N, Swanson S . Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization: The STROBE-MR Statement. JAMA. 2021; 326(16):1614-1621. DOI: 10.1001/jama.2021.18236. View

Romer F . Angiotensin-converting enzyme and its association with outcome in lung cancer. Br J Cancer. 1981; 43(2):135-42. PMC: 2010507. DOI: 10.1038/bjc.1981.21. View

Feng Y, Wan H, Liu J, Zhang R, Ma Q, Han B . The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep. 2010; 23(4):941-8. DOI: 10.3892/or_00000718. View

Wu Z, Yao T, Wang Z, Liu B, Wu N, Lu M . Association between angiotensin-converting enzyme inhibitors and the risk of lung cancer: a systematic review and meta-analysis. Br J Cancer. 2022; 128(2):168-176. PMC: 9670057. DOI: 10.1038/s41416-022-02029-5. View

Lawlor D, Harbord R, Sterne J, Timpson N, Davey Smith G . Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2007; 27(8):1133-63. DOI: 10.1002/sim.3034. View

Emdin C, Khera A, Kathiresan S . Mendelian Randomization. JAMA. 2017; 318(19):1925-1926. DOI: 10.1001/jama.2017.17219. View

10.

Cheng Q, Zhou L, Zhou J, Wan H, Li Q, Feng Y . ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC. Oncol Rep. 2016; 36(3):1403-10. DOI: 10.3892/or.2016.4967. View

11.

Paizis G, Tikellis C, Cooper M, Schembri J, Lew R, Smith A . Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005; 54(12):1790-6. PMC: 1774784. DOI: 10.1136/gut.2004.062398. View

12.

Esteban F, Munoz M, Gonzalez-Moles M, Rosso M . A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 2006; 25(1):137-45. DOI: 10.1007/s10555-006-8161-9. View

13.

Jessup J, Gallagher P, Averill D, Brosnihan K, Tallant E, Chappell M . Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol. 2006; 291(5):H2166-72. DOI: 10.1152/ajpheart.00061.2006. View

14.

Yamaguchi M, Hirai S, Sumi T, Tanaka Y, Tada M, Nishii Y . Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma. Biochem Biophys Res Commun. 2017; 487(3):613-618. PMC: 7092918. DOI: 10.1016/j.bbrc.2017.04.102. View

15.

Bowden J, Davey Smith G, Haycock P, Burgess S . Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol. 2016; 40(4):304-14. PMC: 4849733. DOI: 10.1002/gepi.21965. View

16.

Gilly A, Park Y, Png G, Barysenka A, Fischer I, Bjornland T . Whole-genome sequencing analysis of the cardiometabolic proteome. Nat Commun. 2020; 11(1):6336. PMC: 7729872. DOI: 10.1038/s41467-020-20079-2. View

17.

Kuba K, Imai Y, Ohto-Nakanishi T, Penninger J . Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther. 2010; 128(1):119-28. PMC: 7112678. DOI: 10.1016/j.pharmthera.2010.06.003. View

18.

Takeda Y, Zhu A, Yoneda T, Usukura M, Takata H, Yamagishi M . Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats. Am J Hypertens. 2007; 20(10):1119-24. DOI: 10.1016/j.amjhyper.2007.05.008. View

19.

Heran B, Wong M, Heran I, Wright J . Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2008; (4):CD003823. PMC: 7156914. DOI: 10.1002/14651858.CD003823.pub2. View

20.

Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L . Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol. 2012; 74(1):180-8. PMC: 3394143. DOI: 10.1111/j.1365-2125.2012.04170.x. View